P5-22-01: Feasibility and Patient Safety of Serial Biopsies (bx) in Metastatic HER2−Positive Breast Cancer (BC) To Evaluate Alterations in Molecular Biomarkers (BM): Preliminary Results of SHERsig (Study of HER2 Signature in Metastatic Breast Cancer) a Prospective Phase II Study.
Arlene Chan(Curtin University), Ian O. Ellis(University of Nottingham), A.S. Dhadda(Castle Hill Hospital), Aňa Lluch(Hospital Clínico Universitario de Valencia), Friederike Herbst(Uppsala University Hospital), Henrik Lindman(Uppsala University), Douglas K. Price(Uppsala University Hospital), Astrid Kiermaier(Uppsala University Hospital), Jonas Bergh(Karolinska Institutet), Elisabet Lidbrink(Stockholm South General Hospital), Jane Beith(The University of Sydney), Jacquie Chirgwin(Uppsala University Hospital), José Manuel López-Vega(Uppsala University Hospital), Sally Baron‐Hay(Royal North Shore Hospital), Stephanie Chan(Uppsala University Hospital), Andrew Redfern(Uppsala University Hospital)
Cited by 0
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k